A potential link between autoimmunity and neurodegeneration in immune-mediated neurological disease

Journal of Neuroimmunology

Volumn 235, Issue 1-2, 2011, Pages 56-69

  Lee, Sangmin ^a,b   Xu, Lijing ^c   Shin, Yoojin ^a,b   Gardner, Lidia ^a,b   Hartzes, Anastasia ^a,b   Dohan, F Curtis ^b   Raine, Cedric ^d   Homayouni, Ramin ^c   Levin, Michael C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c University of Memphis   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmunity; Bioinformatics; Multiple sclerosis; Neurodegeneration; Spastin

Indexed keywords

PROTEIN HNRNP A1; RNA; RNA BINDING PROTEIN; SPASTIN; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOIMMUNITY; CELL NUCLEUS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; INTRACELLULAR TRANSPORT; MALE; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE DEGENERATION; PARAPLEGIA; PRIORITY JOURNAL; PROTEIN FUNCTION; SPINAL CORD DISEASE;

ADULT; AGED; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CELL LINE; CELLS, CULTURED; CEREBRAL CORTEX; FEMALE; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE DEGENERATION; YOUNG ADULT;

EID: 79957980963     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.02.007     Document Type: Article

References (90)

1. Aboul-Enein F., Weiser P., Hoftberger R., Lassmann H., Bradl M. Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis. Acta Neuropathol. (Berl.) 2006, 111:539-547.
2. Abramsky O., Lisak R.P., Silberberg D.H., Pleasure D.E. Antibodies to oligodendroglia in patients with multiple sclerosis. N. Engl. J. Med. 1977, 297:1207-1211.
3. Adamus G., Machnicki M., Elerding H., Sugden B., Blocker Y., Fox D. Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J. Autoimmun. 1998, 11:523-533. Oct.
4. Beetz C., Brodhun M., Moutzouris K., Kiehntopf M., Berndt A., Lehnert D., Deufel T., Bastmeyer M., Schickel J. Identification of nuclear localisation sequences in spastin (SPG4) using a novel Tetra-GFP reporter system. Biochem. Biophys. Res. Commun. 2004, 318:1079-1084.
5. Bjartmar C., Kidd G., Mork S., Rudick R., Trapp B.D. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 2000, 48:893-901.
6. Bjartmar C., Wujek J.R., Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 2003, 206:165-171.
7. Brown D.A., Sawchenko P.E. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 2007, 502:236-260.
8. Claudiani P., Riano E., Errico A., Andolfi G., Rugarli E.I. Spastin subcellular localization is regulated through usage of different translation start sites and active export from the nucleus. Exp. Cell Res. 2005, 309:358-369.
9. Clower C.V.0, Chatterjee D., Wang Z., Cantley L.C., Vander Heiden M.G., Krainer A.R. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1894-1899.
10. Cohen M., Reichenstein M., Everts-van der Wind A., Heon-Lee J., Shani M., Lewin H.A., Weller J.I., Ron M., Seroussi E. Cloning and characterization of FAM13A1-a gene near a milk protein QTL on BTA6: evidence for population-wide linkage disequilibrium in Israeli Holsteins. Genomics 2004, 84:374-383.
11. Conti E., Muller C.W., Stewart M. Karyopherin flexibility in nucleocytoplasmic transport. Curr. Opin. Struct. Biol. 2006, 16:237-244.
12. Cook A., Bono F., Jinek M., Conti E. Structural biology of nucleocytoplasmic transport. Annu. Rev. Biochem. 2007, 76:647-671.
13. De Vos K.J., Grierson A.J., Ackerley S., Miller C.C. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008, 31:151-173.
14. DeLuca G.C., Ebers G.C., Esiri M.M. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004, 127:1009-1018.
15. DeLuca G.C., Williams K., Evangelou N., Ebers G.C., Esiri M.M. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006, 129:1507-1516.
16. DeLuca G.C., Ramagopalan S.V., Cader M.Z., Dyment D.A., Herrera B.M., Orton S., Degenhardt A., Pugliatti M., Sadovnick A.D., Sotgiu S., Ebers G.C. The role of hereditary spastic paraplegia related genes in multiple sclerosis. A study of disease susceptibility and clinical outcome. J. Neurol. 2007, 254:1221-1226.
17. Dewji N.N., Shelton E.R., Adler M.J., Chan H.W., Seegmiller J.E., Coronel C. Processing of Alzheimer's disease-associated beta-amyloid precursor protein. J. Mol. Neurosci. 1990, 2:19-27.
18. Dreyfuss G., Kim V.N., Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 2002, 3:195-205.
19. Dutta R., Trapp B.D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007, 68:S22-S31. (discussion S43-54).
20. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59:478-489.
21. Edgington T.S., Dalessio D.J. The assessment by immunofluorescence methods of humoral anti-myelin antibodies in man. J. Immunol. 1970, 105:248-255.
22. Ehlers M.D. Deconstructing the axon: Wallerian degeneration and the ubiquitin-proteasome system. Trends Neurosci. 2004, 27:3-6.
23. El-Fawal H.A., Waterman S.J., De Feo A., Shamy M.Y. Neuroimmunotoxicology: humoral assessment of neurotoxicity and autoimmune mechanisms. Environ. Health Perspect. 1999, 107(Suppl 5):767-775.
24. Evangelou N., DeLuca G.C., Owens T., Esiri M.M. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain 2005, 128:29-34.
25. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120(Pt 3):393-399.
26. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008, 7:852-858.
27. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
28. Ganter P., Prince C., Esiri M.M. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol. Appl. Neurobiol. 1999, 25:459-467.
29. Geis C., Weishaupt A., Hallermann S., Grunewald B., Wessig C., Wultsch T., Reif A., Byts N., Beck M., Jablonka S., Boettger M.K., Uceyler N., Fouquet W., Gerlach M., Meinck H.M., Siren A.L., Sigrist S.J., Toyka K.V., Heckmann M., Sommer C. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010, 133:3166-3180.
30. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 1999, 5:170-175.
31. Geurts J.J., Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008, 7:841-851.
32. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
33. Hanamura A., Caceres J.F., Mayeda A., Franza B.R., Krainer A.R. Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA 1998, 4:430-444.
34. Hazan J., Fonknechten N., Mavel D., Paternotte C., Samson D., Artiguenave F., Davoine C.S., Cruaud C., Durr A., Wincker P., Brottier P., Cattolico L., Barbe V., Burgunder J.M., Prud'homme J.F., Brice A., Fontaine B., Heilig B., Weissenbach J. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat. Genet. 1999, 23:296-303.
35. Homayouni R., Heinrich K., Wei L., Berry M.W. Gene clustering by latent semantic indexing of MEDLINE abstracts. Bioinformatics 2005, 21:104-115.
36. Irizarry R.A., Warren D., Spencer F., Kim I.F., Biswal S., Frank B.C., Gabrielson E., Garcia J.G., Geoghegan J., Germino G., Griffin C., Hilmer S.C., Hoffman E., Jedlicka A.E., Kawasaki E., Martinez-Murillo F., Morsberger L., Lee H., Petersen D., Quackenbush J., Scott A., Wilson M., Yang Y., Ye S.Q., Yu W. Multiple-laboratory comparison of microarray platforms. Nat. Methods 2005, 2:345-350.
37. Jacobson S., Shida H., McFarlin D.E., Fauci A.S., Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990, 348:245-248.
38. Jernigan M., Morcos Y., Lee S.M., Dohan F.C., Raine C., Levin M.C. IgG in brain correlates with clinicopathological damage in HTLV-1 associated neurologic disease. Neurology 2003, 60:1320-1327.
39. Kalume F., Lee S.M., Morcos Y., Callaway J.C., Levin M.C. Molecular mimicry: cross-reactive antibodies from patients with immune-mediated neurologic disease inhibit neuronal firing. J. Neurosci. Res. 2004, 77:82-89.
40. Kamma H., Portman D.S., Dreyfuss G. Cell type-specific expression of hnRNP proteins. Exp. Cell Res. 1995, 221:187-196.
41. Kawamura K., Yao K., Shukaliak-Quandt J.A., Huh J., Baig M., Quigley L., Ito N., Necker A., McFarland H.F., Muraro P.A., Martin R., Ito K. Different development of myelin basic protein agonist- and antagonist-specific human TCR transgenic T cells in the thymus and periphery. J. Immunol. 2008, 181:5462-5472.
42. Kim J.Y., Shen S., Dietz K., He Y., Howell O., Reynolds R., Casaccia P. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 2010, 13:180-189.
43. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 2000, 157:267-276.
44. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J.E., Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
45. Lassmann H. Multiple sclerosis: is there neurodegeneration independent from inflammation?. J. Neurol. Sci. 2007, 259:3-6.
46. Lassmann H., Bruck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218.
47. Lee S., Levin M.C. Molecular mimicry in neurological disease: what is the evidence?. Cell. Mol. Life Sci. 2008, 65:1161-1175.
48. Lee S.M., Morocos Y., Jang H., Stuart J.M., Levin M.C. HTLV-1 induced molecular mimicry in neurologic disease. Current Topics in Microbiology and Immunology 2005, Springer, New York. M. Oldstone (Ed.).
49. Lee B.J., Cansizoglu A.E., Suel K.E., Louis T.H., Zhang Z., Chook Y.M. Rules for nuclear localization sequence recognition by karyopherin beta 2. Cell 2006, 126:543-558.
50. Lee S.M., Dunnavant F.D., Jang H., Zunt J., Levin M.C. Autoantibodies that recognize functional domains of hnRNPA1 implicate molecular mimicry in the pathogenesis of neurological disease. Neurosci. Lett. 2006, 401:188-193.
51. Levin M.C., Jacobson S. HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): a chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system. J. Neurovirol. 1997, 3:126-140.
52. Levin M., Lehky T., Flerlage N., Katz D., Kingma D., Jaffe E., Heiss J., Patronas N., McFarland H., Jacobson S. Immunopathogenesis of HTLV-1 associated neurologic disease based on a spinal cord biopsy from a patient with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). N. Engl. J. Med. 1997, 336:839-845.
53. Levin M., Krichavsky M., Berk J., Foley S., Rosenfeld M., Dalmau J., Chen G., Posner J., Jacobson S. Neuronal molecular mimicry in immune mediated neurologic disease. Ann. Neurol. 1998, 44:87-98.
54. Levin M.C., Lee S.M., Kalume F., Morcos Y., Dohan F.C., Hasty K.A., Callaway J.C., Zunt J., Desiderio D., Stuart J.M. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat. Med. 2002, 8:509-513.
55. Levin M.C., Lee S.M., Morcos Y., Brady J., Stuart J. Cross-reactivity between immunodominant human T lymphotropic virus type I tax and neurons: implications for molecular mimicry. J. Infect. Dis. 2002, 186:1514-1517.
56. Levin M.C., Lee S.M., Morcos Y. Autoimmunity to heterogeneous nuclear ribonucleoprotein in neurological disease. Ann. Neurol. 2005, 57:931.
57. Lily O., Palace J., Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004, 127:269-279.
58. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
59. Lovas G., Szilagyi N., Majtenyi K., Palkovits M., Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000, 123(Pt 2):308-317.
60. Ma J., Chapman G.V., Chen S.L., Melick G., Penny R., Breit S.N. Antibody penetration of viable human cells. I. Increased penetration of human lymphocytes by anti-RNP IgG. Clin. Exp. Immunol. 1991, 84:83-91.
61. Meinl E., Krumbholz M., Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 2006, 59:880-892.
62. Michael W.M., Choi M., Dreyfuss G. A nuclear export signal in hnRNP A1: a signal-mediated, temperature-dependent nuclear protein export pathway. Cell 1995, 83:415-422.
63. Nichols R.C., Wang X.W., Tang J., Hamilton B.J., High F.A., Herschman H.R., Rigby W.F. The RGG domain in hnRNP A2 affects subcellular localization. Exp. Cell Res. 2000, 256:522-532.
64. Norgren N., Edelstam A., Stigbrand T. Cerebrospinal fluid levels of neurofilament light in chronic experimental autoimmune encephalomyelitis. Brain Res. Bull. 2005, 67:264-268.
65. Noseworthy J., Lucchinetti C., Rodriguez M., Weinshenker B. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
66. Oldstone M. Molecular mimicry and immune mediated disease. FASEB J. 1998, 12:1255-1265.
67. Pleasure S.J., Page C., Lee V.M. Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J. Neurosci. 1992, 12:1802-1815.
68. Racke M.K. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr. Opin. Neurol. 2008, 21(Suppl 1):S9-S18.
69. Radic M.Z., Shah K., Zhang W., Lu Q., Lemke G., Hilliard G.M. Heterogeneous nuclear ribonucleoprotein P2 is an autoantibody target in mice deficient for Mer, Axl, and Tyro3 receptor tyrosine kinases. J. Immunol. 2006, 176:68-74.
70. Ratts R.B., Karandikar N.J., Hussain R.Z., Choy J., Northrop S.C., Lovett-Racke A.E., Racke M.K. Phenotypic characterization of autoreactive T cells in multiple sclerosis. J. Neuroimmunol. 2006, 178:100-110.
71. Rawes J.A., Calabrese V.P., Khan O.A., DeVries G.H. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult. Scler. 1997, 3:363-369.
72. Rebane A., Aab A., Steitz J.A. Transportins 1 and 2 are redundant nuclear import factors for hnRNP A1 and HuR. RNA 2004, 10:590-599.
73. Roll-Mecak A., Vale R.D. Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin. Nature 2008, 451:363-367.
74. Ruiz-Arguelles A., Alarcon-Segovia D. Penetration of autoantibodies into living cells, 2000. Isr. Med. Assoc. J. 2001, 3:121-126.
75. Sadatipour B.T., Greer J.M., Pender M.P. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann. Neurol. 1998, 44:980-983.
76. Salinas S., Proukakis C., Crosby A., Warner T.T. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 2008, 7:1127-1138.
77. Schmued L.C., Stowers C.C., Scallet A.C., Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res. 2005, 1035:24-31.
78. Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002, 58:1372-1381.
79. Soderblom C., Blackstone C. Traffic accidents: molecular genetic insights into the pathogenesis of the hereditary spastic paraplegias. Pharmacol. Ther. 2006, 109:42-56.
80. Stewart M. Molecular mechanism of the nuclear protein import cycle. Nat. Rev. Mol. Cell Biol. 2007, 8:195-208.
81. Sueoka E., Yukitake M., Iwanaga K., Sueoka N., Aihara T., Kuroda Y. Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients. Ann. Neurol. 2004, 56:778-786.
82. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
83. Trapp B., Peterson J., Ransohoff R., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
84. Trotta N., Orso G., Rossetto M.G., Daga A., Broadie K. The hereditary spastic paraplegia gene, spastin, regulates microtubule stability to modulate synaptic structure and function. Curr. Biol. 2004, 14:1135-1147.
85. Umehara F., Abe M., Koreeda Y., Izumo S., Osame M. Axonal damage revealed by accumulation of beta-amyloid precursor protein in HTLV-I-associated myelopathy. J. Neurol. Sci. 2000, 176:95-101.
86. Vanderlugt C., Miller S. Epitope spreading. Autoimmunity 1996, 8:831-836.
87. Vincent A. Stiff, twitchy or wobbly: are GAD antibodies pathogenic?. Brain 2008, 131:2536-2537.
88. Vincent A. Successful 'passive transfer' of paraneoplastic stiff person syndrome with antibodies to an intracellular antigen. Brain 2010, 133:3164-3165.
89. Yanase K., Madaio M.P. Nuclear localizing anti-DNA antibodies enter cells via caveoli and modulate expression of caveolin and p53. J. Autoimmun. 2005, 24:145-151.
90. Yuki N., Susuki K., Koga M., Nishimoto Y., Odaka M., Hirata K., Taguchi K., Miyatake T., Furukawa K., Kobata T., Yamada M. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11404-11409.